Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy

Transplantation

Volumn 86, Issue 5, 2008, Pages 652-658

  Akalin, Enver ^a,b   Ganeshan, Sri Venkatesh ^a   Winston, Jonathan ^a   Muntner, Paul ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Chronic allograft nephropathy; Hyperuricemia; Kidney transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAPAMYCIN; TACROLIMUS; URIC ACID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; AGED; ALLOTRANSPLANTATION; BIOPSY; BLOOD; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; RISK; TIME;

ADULT; AGED; BIOPSY; CARDIOVASCULAR DISEASES; FEMALE; GRAFT SURVIVAL; HUMANS; HYPERURICEMIA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 53449101073     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181814f5b     Document Type: Article

References (30)

1. Mazzali M. Uric acid and transplantation. Semin Nephrol 2005; 25: 50.
2. Gores PF, Fryd DS, Sutherland DE, et al. Hyperuricemia after renal transplantation. Am J Surg 1988; 156: 397.
3. Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hy-peruricemia and gout. N Engl J Med 1989; 321: 287.
4. Laine J, Holmberg C. Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children. Nephron 1996; 74: 318.
5. Marcen R, Gallego N, Orofino L, et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995; 70: 307.
6. Zurcher RM, Bock HA, Thiel G. Hyperuricaemia in cyclosporin-treated patients: GFR-related effect. Nephrol Dial Transplant 1996; 11: 153.
7. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183.
8. Johnson RJ, Segal MS, SrinivasT, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 2005; 16: 1909.
9. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endo-thelial dysfunction. Kidney Int 2005; 67: 1739.
10. Gerhardt U, Grosse Huttmann M, Hohage H. Influence of hyperglyce-mia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant 1999; 13: 375.
11. Armstrong KA, Johnson DW, Campbell SB, et al. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 2005; 80: 1565.
12. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
13. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404.
14. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136.
15. Culleton BF, Larson MG, Kannel WB,et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7.
16. Johnson WD, Kayser KL, Brenowitz JB, et al. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991; 121(1 Pt 1): 20.
17. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51.
18. Neal DA, Tom BD, Gimson AE, et al. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation 2001; 72: 1689.
19. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648.
20. Kasiske BL. Ischemic heart disease after renal transplantation. Kidney Int 2002; 61: 356.
21. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66: 441.
22. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807.
23. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71: 900.
24. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237.
25. Hotchkiss H, Chu TT, Hancock WW, et al. Differential expression of profibrotic and growth factorsinchronic allograft nephropathy. Transplantation 2006; 81: 342.
26. Pilmore HL, FaireB, Dittmer I. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. Transplantation 2001; 72: 1703.
27. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppres-sion following renal transplantation. Am J Transplant 2005; 5: 2496.
28. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 2003; 18: 603.
29. Minghelli G, Seydoux C, Goy JJ, et al. Uricosuric effect of the angioten-sin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66: 268.
30. Schmidt A, Gruber U, Bohmig G, et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034.